Spelling suggestions: "subject:"MED/18 chirurgia generales"" "subject:"MED/18 cirurgia generales""
1 |
Utilizzo della rapamicina come farmaco immunosoppressore in pazienti sottoposti a trapianto di fegato per epatocarcinomaCescon, Matteo <1969> 26 September 2007 (has links)
No description available.
|
2 |
Ricerca della tolleranza clinica e recidiva di Epatite C nel trapianto di fegato: effetti a lungo termine dell'induzione con anticorpi policlonali anti-timocitide Ruvo, Nicola <1966> 26 September 2007 (has links)
No description available.
|
3 |
Immunosoppressione farmacologica e recidiva neoplastica in pazienti sottoposti a trapianto di fegato per epatocarcinomaSalone, Mariacristina <1968> 26 September 2007 (has links)
No description available.
|
4 |
Ruolo della rapamicina nei pazienti sottoposti a trapianto di fegato che hanno sviluppato complicanze secondarie all'uso di farmaci inibitori della calcineurinaVarotti, Giovanni <1972> 26 September 2007 (has links)
No description available.
|
5 |
Studi di sicurezza ed efficacia di regimi immunosoppressivi a base di inibitori di mTOR e sospensione degli inibitori delle calcineurine in pazienti sottoposti a trapianto di fegatoMontalti, Roberto <1970> 23 June 2008 (has links)
No description available.
|
6 |
Capacità immunomodulatoria delle cellule staminali mesenchimali in un modello di trapianto d'organo in vivoCavallari, Giuseppe <1972> 23 June 2008 (has links)
No description available.
|
7 |
Incidenza di tumori de-novo nei pazienti trapiantati di fegato: correlazione con i regimi immunosoppressiviDel Gaudio, Massimo <1974> 09 November 2009 (has links)
No description available.
|
8 |
Monitoraggio immunologico con Cylex nel trapianto di fegatoRavaioli, Matteo <1974> 09 November 2009 (has links)
No description available.
|
9 |
Ruolo dell'Infliximab nella terapia della colite ulcerosa moderato-severaMorselli, Claudia <1975> 09 November 2009 (has links)
Background: Almost 10-15% of patients with active Ulcerative Colitis are refractory to conventional therapy. Infliximab is a treatment of proven efficacy in this group of patients.
Aims: To evaluate the role of Inliximab in inducing and maintaining remission in patients with chronically active moderate-severe Ulcerative Colitis. Materials and methods: 53 patients were enrolled, 47 patients entered the study and were treated with a dose of 5 mg/kg. The remission was evaluated through endoscopy and clinical criteria. (Mayo Score). The primary endpoint were clinical and endoscopic remission in moderate-severe Ulcerative Colitis refractory to standard therapy, the secondary out point was the maintenance of remission in the long period.
Results: 47 patients started the study, 43 completed the study, 4 dropped out for worsening disease or adverse events; 27 patients were treated with 3 infusions, 9 patients with 4 infusions, 7 patients with > o = 5 infusions. 34 /47 patients (72.3%) were responders 12 (25.5%) improved their symptoms, 22 ( 46.8%) were in remission after the treatment. Among the responders, 21/34 (61.8%) stopped the steroid therapy after 3 infusions, the others reduced the dose or maintained just topic therapy. 13/47 patients (27.7%) were non responders (p <0.001). After 3 months all 22 patients which had reached remission maintained low Mayo Score; 10/12 (83.3%) patients with clinical response maintained their low score, 2 relapsed . Conclusions: Infliximab is a valid therapy for the treatment of Ulcerative Colitis and can avoid surgery in selected patients.
|
10 |
Sviluppo di un modello sperimentale di insufficienza epatica acuta post- ischemica nel suinoPacilé, Vincenzo <1975> 12 May 2010 (has links)
No description available.
|
Page generated in 1.4026 seconds